Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University College London

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

New study links hearing restorative devices to slower rate of memory decline

The use of hearing aids and cochlear implants reduced long-term cognitive decline by 19%

- PMLiVE

Lilly’s donanemab shows promise in early symptomatic Alzheimer’s comparator study

Brain amyloid clearance was achieved in 37.9% of patients treated with the investigational antibody

- PMLiVE

New study links antioxidant flavonols to slower rate of memory decline

Flavonols are found naturally in fruits, vegetables and in plant products

- PMLiVE

New evidence review uncovers ‘significant’ link between particulate matter and dementia

Information from 17 existing studies was reviewed, involving 91 million people

- PMLiVE

Longitude Prize on Dementia launches innovator hackathons to those aiming for £1m grand prize

The prize will award a total of £4.34m for technology-based tool for people living with dementia

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

Michael J Fox Foundation awards $4.9m grant to Muna Therapeutics

The grant will support the development of the company’s disease modifying therapy for Parkinson's disease

- PMLiVE

New study links omega-3 intake in midlife to reduced dementia risk

Over 2,000 people who did not have dementia or stroke took part in the study

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

- PMLiVE

Alzheimer’s Research UK announces ‘record’ financial performance for 2021/22

The charity was forced to put much of its activity on hold due to the COVID-19 pandemic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links